Turalio, also known as pexidartinib, is a medication that has been approved by the FDA for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adults. TGCT is a rare type of tumor that affects the synovium, which is the lining of joints, tendons, and bursae. This condition can cause pain, swelling, and limited range of motion in the affected joint.

Turalio works by inhibiting certain enzymes that are involved in the growth and survival of the tumor cells. By targeting these specific pathways, Turalio can help to shrink the tumor and alleviate symptoms associated with TGCT.

It is important to note that Turalio is not suitable for everyone and should only be used under the supervision of a healthcare provider experienced in the treatment of TGCT. Before starting Turalio, patients should undergo a thorough evaluation to determine if they are a suitable candidate for this medication.

As with any medication, Turalio can cause side effects, some of which may be serious. Common side effects of Turalio include changes in liver function tests, hair color changes, fatigue, and nausea. Patients should report any new or worsening symptoms to their healthcare provider promptly.

Overall, Turalio represents a promising treatment option for adults with symptomatic TGCT. By working with your healthcare team and closely monitoring your progress, you can help ensure the best possible outcome while taking Turalio. If you have any questions or concerns about this medication, do not hesitate to reach out to your healthcare provider for guidance and support.